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Abstract
Human papillomaviruses (HPV) infect stratified epithelia and restrict expression of late capsid genes
to highly differentiated cells. In order to begin to understand the processes regulating HPV 31
infection we examined the synthesis of the HPV 31 capsid proteins, L1 and L2, using heterologous
expression systems. Similar to studies in HPV 16, expression of wild type HPV 31 L1 and L2 from
heterologous promoters resulted in very low levels of synthesis. In contrast, modification of the
codons in the capsid genes to ones more commonly used in cellular genes resulted in high-level
synthesis. Through the use of chimeric proteins that fused fragments of wild type L1 to Green
Fluorescent Protein (GFP) coding sequences, a short region was identified that was sufficient to
inhibit high level synthesis and similar elements were detected in L2. One element was localized to
the 3' end of the L1 gene while a series of elements were localized at the 3' end of the L2 coding
sequences. These observations are most consistent with negative RNA regulatory elements
controlling the levels of L1 and L2 synthesis that are distinct from those identified in HPV 16.
Expression vectors for the codon modified HPV 31 capsid proteins were then transfected together
with GFP reporter plasmids to generate HPV 31 pseudoviruses. Infection of cells with HPV 31
pseudoviruses in the presence of the inhibitors, chlorpromazine, nystatin or methyl-beta-
cyclodextrin, demonstrated that HPV 31, like HPV 16, enters human and monkey cells through a
clathrin-mediated pathway rather than through caveolae as previously reported. This suggests that
high-risk HPV types may enter cells through common mechanisms.
Background
Papillomavirus are non-enveloped, small double-
stranded DNA viruses that target epithelial tissue for infec-
tion [1]. More than one hundred different types of human
papillomaviruses (HPV) have been identified [2] and
approximately one third of these types infect the anogeni-
tal epithelium. Infections by genital papillomaviruses are
one of the most common sexually transmitted viral infec-
tions. The viruses that infect the genital tract are further
classified as either high risk or low risk viruses. Low risk
viruses induce benign warts that rarely progress to malig-
nancy. In contrast, infections by high-risk HPV types can
lead to the development of cervical cancer which is one of
the most common cancers worldwide [1,3,4].
Infection by HPV's is believed to occur following micro-
traumas of the epithelia that expose the basal cells to entry
[1,3]. Following entry into cells, the viral genomes are
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established as nuclear plasmids. Infected cells in the stra-
tum basale maintain viral genomes at approximately 50
copies and transcription is limited to the early genes [4].
Expression of early transcripts is directed primarily from a
promoter upstream of E6 and the early gene products reg-
ulate viral gene expression, viral genome replication and
cellular transformation.
The productive phase of the papillomavirus life cycle is
keyed to the differentiation program of the infected kerat-
inocytes [4]. As cells in the basal layer divide, one of the
daughter cells migrates towards the upper epithelial lay-
ers. Normal uninfected epithelial cells exit the cell cycle as
they leave the basal layer and begin a program of terminal
differentiation. In contrast, HPV infected cells remain
active in the cell cycle through the action of HPV early
genes E6 and E7. A subset of infected suprabasal cells re-
enter S-phase and amplify viral genome copy numbers to
thousands of copies per cell. Concomitant with genome
amplification is activation of the late promoter which
directs expression of the E1^E4, E5 late proteins as well as
the capsid proteins L1 and L2. Expression of capsid pro-
teins is restricted to differentiated epithelial cells and is
regulated by both transcriptional and post-transcriptional
mechanisms.
HPV virions have been produced in the laboratory
through the use of organotypic raft cultures [5]. These cul-
tures allow for the growth of cells at the air-liquid inter-
face, resulting in differentiation of the keratinocytes.
When epithelial cells that maintain HPV episomes are
grown in rafts, virus production occurs in the upper strata
[5-7]. The titers of virus produced from these cultures are
low and this has limited the use of these reagents for
investigating the papillomavirus infectious life cycle [8].
Alternative methods to study HPV infection include the
use of viral-like particles (VLPs) as well as pseudoviruses
which encapsidate reporter genes inside VLPs [9-11].
The mechanisms that regulate HPV entry into cells are
beginning to be elucidated. Initial binding of HPVs is
thought to occur on many cell types through an associa-
tion with heparin sulfate and this is likely followed by
engagement of additional receptor proteins on the cell
surface [12-14]. Many DNA viruses enter cells through
one of two dynamin-dependent pathways involving use
of caveolae or clathrin coated pits [15,16]. Caveolae are
invaginations of the plasma membrane that are associated
with lipid rafts and are stabilized by the presence of cho-
lesterol and caveolin. Caveolae vesicles traffic virions to
the smooth endoplasmic reticulum via a process that is
independent of endosomes or lysosomes. SV-40 and
echoviruses 1 both use the caveolae pathway to enter cells
[17,18]. An alternate pathway for viral entry utilizes clath-
rin coated pits. In clathrin mediated entry, virions are
transported into endosomes and lysosomes. The use of
inhibitors that can discriminate between these two path-
ways has been used to study the mechanisms used by dif-
ferent viral types. These inhibitors include nystatin and
methyl-β-cyclodextran which chelate cholesterol resulting
in the destabilization of the lipid rafts and prevention of
caveolae formation. Similarly, chlorpromazine is an
inhibitor of clathrin pathway that prevents endocytosis by
preventing the release of clathrin from the endosomes
[19,20]. Using these inhibitors together with pseudovirus
systems, HPV 16, HPV 33 and BPV 1 have been reported
to enter cells by the clathrin mediated pathway
[10,11,21]. In contrast, HPV 31 VLPs have been reported
to enter cells via the caveolae pathway [21].
In this study we found that the synthesis of wild type HPV
31 L1 and L2 proteins from heterologous expression sys-
tems was quite low, however, modification of codons to
those more frequently in human genes resulted in high
levels of protein synthesis. Our studies further indicate
that codon usage itself was probably not the source of the
low levels of synthesis but rather was due to the presence
of RNA inhibitory elements present in both L1 and L2.
These negative regulatory elements are distinct from those
previously identified in HPV 16. We then used HPV 31
pseudovirions generated from codon modified capsid
proteins to demonstrate that entry occurred through a
clathrin-mediated pathway in manner similar to HPV 16.
Results
Expression of wild type and codon optimized HPV 31 L1 
and L2
In order to investigate the mechanisms that regulate HPV
31 capsid assembly and virion entry, we sought to express
high levels of capsid proteins using transient transfection
assays. Plasmids expressing the HPV 31 wild type L1 gene
from SV40 promoters were transfected into Cos-7 cells
and after 72 hours, proteins extracts analyzed by Western
analysis. In multiple experiments, we failed to observe sig-
nificant levels of synthesis of L1 (Figure 1). Similar exper-
iments were performed with HPV 31 L2 and yielded
comparable low levels of expression (data not shown).
Examination of the HPV 31 L1 and L2 coding sequences
identified a large number of codons not commonly found
in most higher eukaryotic genes and this is similar to that
found in other high-risk HPV types [9,22]. Use of these
particular codons in HPV 31 results in an unusually low
G-C content. It was possible that the low level of expres-
sion we observed with HPV 31 capsid proteins was due
either to inefficient translation resulting from use of rare
codons or to the presence of negative regulatory elements
in the RNA [9,22]. We therefore altered the L1 codon
usage in a two-step process reasoning that this would
increase the levels of protein synthesis by either eliminat-
ing any negative regulatory elements or altering translata-Virology Journal 2007, 4:19 http://www.virologyj.com/content/4/1/19
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bility. Similar modification of codons in HPV 16 L1 has
been reported to result in increased levels of protein
expression [9].
First, we altered the coding sequences in HPV 31 L1 to
include those codons used frequently in human genes. We
then identified codons that had not been changed by this
analysis and altered them to the second most frequently
used. As a result, by adding this last modification, we
introduced at least one base change in almost every codon
of L1. The final sequence is referred to as CoOpHPV 31 L1.
This optimization of HPV 31 L1 increased the GC content
of HPV 31 L1 from 38 to 58 percent. The entire codon
optimized sequence for HPV 31 L1 will be deposited in
GenBank. Our approach to the codon optimization of
HPV 31 L2 was very similar to the method we used for
HPV 31 L1. For L2, the GC content was increased from 41
to 59 percent. The entire codon optimized sequence for
HPV 31 L2 will also be deposited in GenBank.
Identification of negative regulatory elements in HPV 31 
L1 and L2
We next examined if these changes in codon usage
resulted in increased HPV 31 L1 and L2 protein synthesis.
Western analysis of HPV 31 L1 Figure 1
Western analysis of HPV 31 L1. (Panel A). Cos-7 cells were transfected with pcDNA 3.1(-) expression vector expressing 
either wild type HPV 31 L1 or codon optimized HPV 31 L1. After 72 hours, lysates were harvested and analyzed by Western 
analysis with and antibody to L1. Lane A mock transfected Cos-7 cells. Lane B wild type HPV 31 L1. Lane C Codon optimized 
HPV 31 L1. Lanes D and E contain L1 peptides tagged with GFP and probed using a GFP antibody. Lane D wild type HPV 31 L1 
N-terminus. Lane E wild type HPV 31 L1 C-terminus. (Panel B). Western analysis of in frame fusions to GFP of 198 base pair 
fragments from the C-terminal domain of wild type L1 following transfection into Cos-7 cells. Each fragment overlapped with 
the adjacent fragment by 99 base pairs. Following transfection cell extracts were analyzed by Western analysis using a GFP anti-
body. Lane A plasmid A, GFP fusion to nucleotides 6209–6407 Lane B fragment 2, nucleotides 6308–6506. Lane C fragment 3, 
nucleotides 6407–6605. Lane D fragment 4, nucleotides 6506–6704. Lane E fragment 5, nucleotides 6605–6803. Lane F frag-
ment 6, nucleotides 6704–6902. Lane G fragment 7, nucleotides 6803–7063. Cartoon shows the fragments of L1 that were 
fused to GFP and examined in the experiments in panel C. Nucleotide numbers correspond to those in HPV 31 genome.
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Codon optimized HPV 31 L1 and L2 were cloned into
SV40 based expression vectors and transfected into Cos-7
cells along with wild type expression vectors. As shown in
Figure 1, alteration of the coding sequence resulted in
high level of expression of codon optimized L1. Since our
L2 antibody had a high background, we tagged wild type
and codon optimized L2 with a GFP tag and screened L2-
GFP protein levels using an antibody to GFP. Similar to
our observations with HPV 31 L1, Cos-7 cells transfected
with codon optimized L2 tagged to GFP expressed high
levels of protein in comparison to tagged wild type L2
which were not detectable (Figure 2).
Studies were then undertaken to determine if the increase
in L1 synthesis was due to more efficient translation due
to the use of more commonly used codons or through the
elimination of negative regulatory elements present in the
L1 RNA. For this analysis we investigated the effect of
altering codons on the expression of the N and C-terminal
halves of HPV 31 L1. We reasoned that if inefficient syn-
thesis was due to rare codon usage then we should see
similarly low levels of expression of both N and C-termi-
nal peptides as seen with the whole L1 protein. Alterna-
tively if RNA negative regulatory elements were present in
either half of the protein and these were responsible for
low levels of expression then we would see high levels of
expression with one truncated protein but not the other.
We constructed two plasmids in which the N and C ter-
mini of L1 were fused in frame with GFP coding sequences
as this allowed for a direct comparison of protein synthe-
sis levels using an antibody to the common tag. The plas-
mids were transfected into Cos-7 cells and after 72 hours
protein extracts were examined by Western analysis. We
observed high levels of expression of the fusion of GFP to
the wild type HPV 31 L1 N-terminus and barely detectable
levels of the C terminal fusion (Figure 1). No such differ-
ences in expression levels were seen between codon-mod-
ified N and C terminal peptides (data not shown). Since
the distribution of codons is similar between the two
halves of the L1 protein, our data are consistent with the
presence of a negative regulatory element present in the 3'
end of the L1 coding sequence. In order to localize this
element, we next constructed a series of GFP fusions in
which a sequential series of 198 nucleotide DNA frag-
ments from the 3' end of L1 were fused in frame to GFP
coding sequences. These plasmids were transfected into
cells, extracts isolated after 72 hours and analyzed for GFP
protein levels by Western analysis. As shown in Figure 1B,
fusion of sequences 6407 to 6605 significantly reduced
levels of GFP protein synthesis identifying a major regula-
tory element in this region. Nucleotide numbers corre-
spond to those in complete HPV 31 genome.
We next investigated if L2 coding sequences exhibited
similar properties. Using methods comparable to those
for the analysis of L1, N and C terminal fusions of the wild
type L2 coding sequences were made to GFP. Expression
vectors containing these fusions were then transfected
into Cos-7 cells and protein extracts isolated after 72
hours. Western analysis revealed that the N terminal
fusion to GFP was synthesized at high levels while the C
terminal fusion peptide was not detectable (Figure 2A).
We next constructed a series of in frame fusions of 198
base pair fragments isolated from the 3' end of wild type
L2 to GFP sequences. Each fragment overlapped with the
adjacent fragment by 99 base pairs. As shown in Figure 2B,
the three fusions that spanned the region of 699 to 1098
exhibited reduced levels of GFP expression though no sin-
gle element had as marked an effect as that seen with the
fusion of the complete 3' end of the L2 coding sequence.
This suggested that there are multiple elements may be
present that act cooperatively to reduce levels of L2. We
next performed RT-PCR on RNA isolated from the trans-
fections of the various L2 constructs fused to GFP. In the
RT-PCR reaction we used primers specific to the GFP por-
tion since GFP was common to all constructs to confirm
that the observed reduction was mediated at the RNA
level. Consistent with our hypothesis of the presence of an
RNA inhibitory element, we noted a corresponding reduc-
tion in transcript levels in cells transfected with fusions
that spanned 4870 to 5266 (Figure 2C) while transfec-
tions with the A and E plasmids exhibited higher message
levels. The reduced levels of transcripts observed with the
F and G plasmids along with their corresponding high lev-
els of proteins synthesis suggest additional mechanisms
may also exist to regulate expression. To provide further
support for our hypothesis regarding the presence of mul-
tiple elements, we constructed a series of C-terminal dele-
tions of the wild type L2 fusion with GFP and transfected
these vectors into Cos-7 cells. As shown in Figure 2D,
deletion of sequences 5568 to 5068 restored detectable
levels of synthesis, which was further enhanced by dele-
tion to nucleotide 4969. Our results are consistent with
the presence of a cooperative series of negative regulatory
elements in the 3' end of the L2 coding sequence.
Assembly of codon optimized HPV 31 pseudovirions
We next sought to use the optimized expression vectors to
L1 and L2 to study HPV 31 entry mechanisms. Previous
studies have reported the generation of pseudoviruses by
the expression of codon optimized HPV 16 L1 and L2
along with reporter plasmids. [9,23]. We utilized a com-
parable system to study HPV 31 entry by including a plas-
mid containing a GFP reporter driven by a CMV promoter.
The reporter plasmid also contained a region of HPV 31
that encompasses the E1 open reading frame. A similar
region in the BPV 1 E1 open reading frame has been
reported to enhance the packaging of DNA into viral par-
ticles [24]. This reporter plasmid is approximately 8 kb in
size and is similar to that of the 7.9 kb HPV 31 genome.Virology Journal 2007, 4:19 http://www.virologyj.com/content/4/1/19
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Recently smaller vectors of 6.0 kb in size have been sug-
gested to be packaged more efficiently than larger plas-
mids that approximate the size of the viral genome [23].
However, in our studies, pseudovirions that encapsulate
an 8.0 kb plasmid were found to be as infectious as pseu-
dovirions that encapsulate a 6.0 kb vector (data not
shown).
In order to produce HPV 31 pseudovirions, we electropo-
rated Cos-7 cells with three separate plasmids consisting
of our codon optimized HPV 31 L1 and L2 expressed from
the CMV promoter along with the GFP reporter plasmid.
We screened for L1 synthesis by Western analysis as well
as GFP expression by immunofluoresence and found that
expression levels of proteins were highest at 72 h follow-
Western analysis of HPV 31 L2 Figure 2
Western analysis of HPV 31 L2. Cos-7 cells were transfected with GFP tagged L2 in pcDNA 3.1(-) expression vectors. 
After 72 hours, lysates were harvested and analyzed by Western blot with an antibody to GFP. (Panel A). Lane A: wild type 
HPV 31 L2. Lane B: wild type HPV 31 L2 N-terminus. Lane C: wild type HPV 31 L2 C-terminus. Lane D: codon optimized HPV 
31 L2. (Panel B). Western analysis of transfections of GFP in frame fusions to 198 base pair fragments of the C-terminal domain 
of wild type L2. Each fragment overlapped with the adjacent fragment by 99 base pairs. Cell extracts were examined by West-
ern analysis using a GFP antibody. Lane A: fragment A, GFP fusion to nucleotides 4771–4969. Lane B: fragment Bnucleotides 
4870–5068. Lane C: fragment C, nucleotides4969–5167. Lane D: fragment D, nucleotides5068–5266. Lane E: fragment E, 
nucleotides5167–5365. Lane F: fragment F nucleotides 5266–5464. Lane G: fragment G, nucleotides5365–5568. (Panel C). RT-
PCR analysis of RNAs isolated from cells transfected with plasmids shown in panel B. Primers to common GFP sequences were 
used in this analysis. (Panel D) Lane A: mock transfected cells. Lane B: complete wild type HPV 31 L2 fused to GFP nucleotides 
4171–5568. Lane C: N-terminal domain wild type L2 (nucleotides 4171–4870) fusion to GFP. Lane D: C-terminal domain wild 
type L2 (nucleotides 4870–5568) fused to GFP. Lane E: N-terminal domain wild type L2 (nucleotides 4171–4969) fused to GFP. 
Lane F: N-terminal domain wild type L2 (nucleotides 4171–5068) fused to GFP. Lane G: N-terminal domain wild type L2 
(nucleotides 4171–5166) fused to GFP. Lane H: N-terminal domain wild type L2 (nucleotides 4171–5265). Lane I: N-terminal 
domain wild type L2 (nucleotides 4171–5465). Cartoon identifies fragments of L2 fused to GFP examined in lanesE – I. Nucle-
otide numbers are those in HPV 31 genome.
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ing electroporation (data not shown). Similar effects were
seen with human 293TT cells. In our subsequent experi-
ments, we therefore harvested pseudoviruses at 72 hours.
Following transfection, cells were harvested, pelleted and
resuspended in PBS followed by to 4 to 6 rounds of freeze-
thaw. The lysed cells were then treated with DNase 1 and
incubated for 1 h at 37°C. The treated lysate solution was
brought to a final concentration of 0.8 M NaCl and incu-
bated for 1–3 h at 37°C. The lysate was then centrifuged
at low speed, which removes the cellular debris but allows
the pseudovirions to remain in the supernatant. Previous
studies using similar protocols have shown HPV 16 pseu-
dovirions are retained in the supernatant [23].
Analysis of entry pathway used by HPV 16 and 31 
pseudovirions
We next used our HPV 31 pseudovirions to examine the
parameters that influence entry. HPV 31 pseudovirion
preparations were added to sub-confluent, monolayer
cultures of Cos-7 or 293TT cells and incubated for various
periods of time. The cells were then fixed and analyzed by
fluorescence microscopy. We observed initial fluorescence
at approximately 36 hours post infection that peaked at
72 hours. Figure 3 shows representative GFP expression in
Cos-7 and 293 TT cells that are positive for HPV 31 pseu-
dovirion infection at 72 hours post-infection. GFP expres-
sion occurs only if the genome has been transported to the
nucleus and the reporter plasmid has been transcribed
[25]. Production of HPV 31 pseudovirions and infectivity
was found to be significantly higher in 293 TT cells than
Cos-7 cells.
In order to compare the different entry pathways used by
various HPV types, we included control infections using
similarly isolated preparations of HPV 16 pseudoviruses.
To generate HPV 16 pseudoviruses, we transfected expres-
sion vectors for codon optimized HPV 16 L1 and L2 [9]
from Martin Mueller's lab along with the same GFP
reporter plasmid into Cos-7 or 293 TT cells. HPV 16 pseu-
dovirions were isolated by the same procedure used for
HPV 31 pseudoviruses and added to sub-confluent Cos-7
or 293 TT cells. After 72 hours, the cells were fixed and
analyzed by fluorescence microscopy. We observed the
first GFP signal at 36 hours after infection with a time
course that was similar to our HPV 31 infections (data not
shown). Again as we found with HPV 31, production of
HPV 16 pseudovirions and infectivity was significantly
higher in 293 TT cells than Cos-7 cells.
HPV 31 has been previously reported to enter cells
through the caveolae pathway while other high-risk HPV
types such as HPV 16 and 33 utilize clathrin coated pits to
transit into the cell [11,21]. We sought to investigate the
process by which HPV 31 pseudoviruses entered cells
through the use of inhibitors of caveolae/lipid rafts such
as nystatin and methyl-β-cyclodextrin as well as chlorpro-
mazine which impedes clathrin entry [26-28]. In our stud-
ies we used the same concentrations used in the previous
experiments with pseudoviruses.
We next wanted to confirm, using our experimental pro-
tocols, that HPV 16 pseudoviruses enter cells by the clath-
rin mediated pathway as has been reported [10-12]. In
these experiments we added the inhibitors (either nysta-
tin, methyl-β-cyclodextrin or chlorpromazine) 30 min-
utes prior to infection and maintained for 72 h. In Figure
4, averaged results from three experiments are shown in
which Cos-7 and 293 TT cells were infected with HPV 16
pseudovirions in the presence or absence of inhibitors.
Similar results were seen in multiple experiments. As the
concentration of chlorpromazine was increased, we
observed a significant decrease in HPV 16 pseudovirion
entry (Figure 4). In contrast, the presence of nystatin and
methyl-β-cyclodextrin exhibited no effect on HPV 16
pseudovirion infectivity. These concentrations have been
reported to inhibit the infection by BPV-1, HPV 33 and
EBV [10,11,21,26]. We next performed identical experi-
ments with HPV 31 pseudoviruses and the results are
shown in Figure 5. As we observed with HPV 16 pseudo-
viruses, increasing concentrations of chlorpromazine
decreased HPV 31 pseudovirion entry in a dose-depend-
ent manner into either Cos-7 or 293 TT cells. The concen-
trations of inhibitors used in Figure 5 had no effect on cell
viability but higher concentrations of chlorpromazine
were observed to be toxic to the Cos-7 and 293 TT cells
(data not shown). As shown in Figure 5, no decrease on
HPV 31 pseudovirion infectivity was observed as nystatin
or methyl-β-cyclodextrin levels were increased. Interest-
ingly, at intermediate concentrations of nystatin or
methyl-β-cyclodextrin, we observed a reproducible
increase in infectivity over untreated cells. In addition we
observed that treatment with the drugs was reversible, as
infections in the presence of chlorpromazine for 2–6
hours followed by a wash with fresh media and incuba-
tion for a total of 72 hours had negligible effect on infec-
tivity (data not shown). Our results suggest a role for
clathrin-mediated entry of HPV 16 and 31 pseudovirions
in the entry of human and monkey cells.
Discussion and conclusion
In this study we have examined the regulation of HPV 31
capsid protein synthesis and the mechanism of viral entry.
The expression of capsid proteins of papillomaviruses
occurs late in the viral life cycle in terminally differenti-
ated epithelial cells. This restriction has limited the full
understanding of the papillomavirus life cycle. In tran-
sient overexpression assays using heterologous promoter
constructs, we observed that the levels of synthesis of wild
type HPV 31 L1 and L2 protein were so low that they were
not detectable by standard Western analysis. We reasonedVirology Journal 2007, 4:19 http://www.virologyj.com/content/4/1/19
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that this low level synthesis was the result of the presence
in L1 and L2 of rare codons that are infrequently found in
mammalian genes. When these codons were modified to
ones more commonly found in human coding sequences,
the levels of synthesis of the capsid proteins increased sig-
nificantly. The presence of infrequently used codons does
not appear alone to be sufficient to limit expression of the
late proteins as a similar frequency of rare codon usage is
found in other HPV 31 ORF's including those for E1, E2,
E5, E6 and E7. Utilization of infrequently used codons
could contribute to low levels of viral protein translation
and so aid in escaping immune detection. However, since
the capsid proteins are only synthesized in highly differ-
entiated cells, which are located at a distance from most
antigen presenting cells this does not seem to be a likely
explanation. An alternate hypothesis is that the tRNAs
encoding these infrequently used codons are more abun-
dant in differentiating keratinocytes, but there is no con-
vincing evidence for such a cell type specific distribution
of tRNAs in human keratinocytes.
Infection of Cos-7 and 293 TT cells by HPV 31 and HPV 16 pseudovirions Figure 3
Infection of Cos-7 and 293 TT cells by HPV 31 and HPV 16 pseudovirions. (A). HPV 31 pseudovirions were used to 
infect Cos-7 cells (left panel) or 293 TT cells (right panel). (B). HPV 16 pseudovirions were used to infect Cos-7 cells or 293 
TT cells (right panel). After 24 hours, the media was changed. The infection was allowed to proceed for a total of 72 hours 
where maximal GFP expression occurred. The cells were fixed and stained with DAPI. Shown is a representative field of 
infected cells detected by GFP fluorescence.
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Our studies provide evidence that utilization of rare
codons in HPV 31 results from the presence of negative
regulatory elements in the mRNAs themselves that likely
regulate stability of late messages. In HPV 16, a negative
regulatory element was identified at the 5'end of L1 and
regulates usage of the upstream splice site [29-31]. The
negative element we identified in HPV 31 is located at the
3' end of the L1 open reading frame and did not function
by altering splicing. An additional series of negative ele-
ments have been identified in HPV 16 L2 but in contrast
to our studies with HPV 31, these elements are located at
the 5' end as well as in the middle of L2 [36]. In HPV 31,
we found a series of cooperative elements localized to the
3' end of the open reading frame. It is unclear whether the
HPV 31 elements may act in a similar manner to those of
HPV 16. It is also possible that an unequal distribution of
a small set of rare codons that are localized to these ele-
ments contribute to reduced levels of synthesis. Further
analysis will require alteration of these elements in the
context of the complete HPV genome and screening for
effects on the viral life cycle following differentiation.
The RNA inhibitory elements we identified in the L1 and
L2 genes of HPV 31 may act to regulate the stability or
translatability of late mRNAs. These elements may be rec-
ognized by trans acting factors that are modulated upon
differentiation to allow for capsid proteins synthesis in
suprabasal cells. Several cellular factors have been
reported to negatively regulate the stability of capsid tran-
scripts of various papillomaviruses including heterogene-
ous ribonucleoprotein K (hnRNP K), hnRNP C, poly (rC)
binding-protein (PCBP), U1 snRNP and HuR [29-35].
Similar to our studies on HPV 31, the optimization of cap-
sid sequences for HPV 11, 16 and BPV 1 have been shown
to increase levels of protein synthesis and may contain
similar elements [9,36,37]. Our studies are consistent
with important roles for these negative regulatory ele-
ments in the pathogenesis of high risk HPVs.
The HPV 31 pseudovirions synthesized using the codon
optimized capsid proteins were then used together with a
GFP reporter plasmid to investigate the mechanisms by
which these viral types enter cells. Previous studies used
HPV 31 VLPs to which DNA reporter plasmids had been
adhered on the external surface to examine pathways by
which HPVs enter cells [21]. Using inhibitors of the clath-
rin-mediated and caveolae pathways, it was reported that
HPV 16 entered cells by the clathrin-mediated mechanism
Inhibition of HPV 16 pseudovirion infection Figure 4
Inhibition of HPV 16 pseudovirion infection. (A) Cos-7 cells or (B) 293 TT cells were treated with inhibitors chlorpro-
mazine, nystatin or methyl-β-cyclodextran at the concentrations shown for 30 min prior to infection. The cells were infected 
over night with HPV 16 pseudovirions. Media was changed at 24 hours, fresh media and drug was added. The infection was 
allowed to continue for an additional 48 hours for a total of 72 hours. Percentage GFP positive cells relative to control is 
shown. Each panel is an average of 3 experiments.
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while HPV 31 entered by caveolae. The ability of HPV 16
pseudovirions to enter cells by a clathrin-mediated path-
way had been also reported by John Schiller's group [10].
In our study, we examined entry using our HPV 31 pseu-
dovirions in the presence of the caveolae inhibitors nysta-
tin and methyl-β-cyclodextrin along with
chlorpromazine, which inhibits clathrin mediated uptake.
We observed that like HPV 16, HPV 31 entry was inhibited
only by chlorpromazine indicating entry occurs via the
clathrin-mediated pathway. We suspect that the previous
use of VLP's to which reporter plasmids were coupled on
the external surface may have altered the pathway by
which HPV 31 normally enters cells. Our data are consist-
ent with the idea that the oncogenic HPV types enter cells
by a common mechanism. We cannot, however, exclude
the possibility that there are cell type specific differences
in the mechanisms by which HPV 's enter cells and that
there might be cells where HPV 31 uses caveolae to enter
cells. The identification of a common pathway used by
high risk HPV types suggests that antivirals could be devel-
oped that target clathrin-mediated entry to block infec-
tions by these highly pathogenic viruses.
Methods
Codon optimization of HPV 31 L1 and L2
To codon optimize L1 and L2, the sequence was recoded
to reflect the most common codons used by human cells.
This sequence was then aligned with the wild type
sequence using Lasergene MegAlign (Madison Wi,
53715). Any identical codons identified in the alignment
were changed to a different codon, usually the most com-
mon codon for that given amino acid. The sequences were
Inhibition of HPV 31 pseudovirion infection Figure 5
Inhibition of HPV 31 pseudovirion infection. (A) Cos-7 cells or (B) 293 TT cells were treated with inhibitors chlorpro-
mazine, nystatin or methyl-β-cyclodextran at the concentrations shown for 30 min prior to infection. The cells were infected 
over night with HPV 31 pseudovirions. Media was changed at 24 hours, fresh media and drug was added. The infection was 
allowed to continue for an additional 48 hours for a total of 72 hours. Percentage GFP positive cells relative to control is 
shown. Each panel is an average of 3 experiments.
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synthesized by DNA 2.0 (Menlo Park, CA 94025) and
cloned into a pDrive cloning vector (Qiagen, Hilden Ger-
many).
Plasmids constructs
The reporter plasmid pHcDNA8k GFP was created by
cloning the green fluorescent protein (GFP) gene (Clon-
tech Mountain View, CA 94043) into Bam H1 and Hind
III sites of pcDNA 3.1 (-) (Invitrogen Carlsbad, California
92008). In addition a fragment of HPV 31 E1 (base pairs
1048–2880) were cloned into the unique Bgl II site of
pcDNA 3.1 (-). Codon optimized HPV 31 L1 and L2
(pHcDCoOp31L1 and pHcDCoOp31L2) and wild type
HPV 31 L1 and L2 (pHcDWT31L1 and pHcDWT31L2)
were cloned into pcDNA 3.1 (-) at Xho1 and Eco R1 sites.
These vectors contain an SV40 origin which allows for rep-
lication in cells that express T-antigen. All primers were
purchased from IDT (Coralville, IA 52241). HPV 16 L1
and L2 constructs were generously provided by Martin
Muller Heidelberg, Germany.
Cell lines and transfections
Cos-7 cells were maintained in Dulbecco's modified Eagle
medium (DMEM) (Invitrogen) and supplemented with
10 percent fetal bovine serum (FBS) (Hyclone Logan
Utah, 84321). 293TT cells (generously provided by John
Schiller, NIH) were maintained in DMEM and 10 percent
FBS supplemented with 1 percent non essential amino
acids (Invitrogen), 1 percent Glutamax 1 (Invitrogen) and
cultured with hygromycin B (Roche). Cells were trans-
fected using a BTX ECM 630 Electro Cell Manipulator
(BTX San Diego Ca 92121) 170 V and 950 μF capacitance.
Typically 1–9 μg of DNA was electroporated along with 1–
2 million cells in 300 μl DMEM and 10 percent FBS using
a 0.4 cm BioRad cuvette (BioRad Hercules Ca 94547).
Western blot analysis and RT-PCR
Cos-7 cells were harvested 72 hours post transfection and
whole cell extracts were prepared using NP-40 lysis buffer
(150 mM NaCl, 50 mM Tris-HCl [pH 8], 5 mM EDTA [pH
8], 0.5 mM dithiothreitol, 100 mM sodium fluoride, 200
μM sodium-orthovanadate, 0.5% NP-40, 1 mM phenyl-
methylsulfonyl fluoride) containing a cocktail of protease
inhibitors (Complete, Mini; Roche Diagnostic). Cell
lysates were cleared of insoluble material by centrifuga-
tion at 12,000 RPM for 10 minutes. The lysates were quan-
titated with the Bradford assay (Bio-Rad). Proteins were
separated using a 10 percent SDS-polyacrylamide gel and
transferred to a polyvinylidene difluoride membrane
(Immobilon-P; Millipore, Bedford, Mass.). The mem-
brane was blocked in wash solution containing 5% nonfat
dry milk, 0.1% Tween 20 in PBS. HPV L1 (HPV16.D9)
monoclonal antibody was a generous gift form Neil Chris-
tensen, Pennsylvania State University College of Medi-
cine, Hershey, PA 17033. Living Colors GFP monoclonal
antibody (JL-8) (Clontech). Sheep anti-mouse HRP
(NA931V) and sheep anti-mouse FITC (N1031V) mono-
clonal antibodies were from Amersham Biosciences UK.
Specific proteins were visualized via enhanced chemilu-
minescence (Amersham-Pharmacia).
Cos-7 cells were electroporated with GFP tagged con-
structs used in Figures 1B and 2B. Total cellular RNA was
isolated using SV Total RNA Isolation System (Promega)
as per manufacturer instructions. 1 ug of total RNA was
used in the RT-PCR reactions (Reverse Transcriptase Sys-
tem, Promega). To amplify the RT product we used prim-
ers to GFP since GFP was common to all constructs used
in these reactions. As a control, reactions were performed
in the absence RT to control for plasmid contamination.
Fluorescent microscopy
Cos-7 cells were electroporated with plasmids or infected
with pseudovirions and grown on glass cover slips (Corn-
ing). After 72 hours the cells were washed in PBS, fixed in
100 percent Methanol, stained with 10 μg/ml DAPI
(Sigma) and allowed to air dry. The cover slips were then
coated with Vectashield, Vector Laboratories, Burlingame
Ca. 94010.
Preparation of HPV 31 and 16 pseudovirions and infection 
of target cells
Cos-7 cells or 293TT cells [23] were electroporated with
L1, L2 and the reporter plasmid as described above. The
cells were allowed to grow for 72 hours and harvested.
Our harvesting method is a modification described by
Buck et al., [23]. Transfected Cos-7 or 293TT cells were
washed with PBS and trypsinsized (Invitrogen). The
trypsin was neutralized with DMEM plus FBS and centri-
fuged at 190 xg for 4 min at room temperature. The pellet
was then washed with PBS and centrifuged as above. The
pellet was resuspended in PBS supplemented with Com-
plete Mini protease inhibitor (Roche, Mannheim, Ger-
many) and subjected to 3–6 rounds of freeze-thawing
(ethanol-dry ice transferred to 37°C water bath). MgCl2
was added to the suspension to a final concentration of
2.5 mM. To remove any free reporter plasmid the pseudo-
virions were treated with 5 units of DNAse 1 (New Eng-
land Biolabs, Beverly, Ma) for 1 hour at 37°C. NaCl was
added to the digested lysate at a final concentration of 0.8
M. The lysate was then incubated at room temperature for
1–3 hours followed by a low speed centrifugation (2000
× g for 10 minutes). The isolated pseudovirions were
maintained on ice prior to infection assays. Cos-7 or
293TT cells were infected with 1/10 volume of the pseu-
dovirion supernatant. At 24 hours post infection, the
media was replaced and the infection continued for an
additional 48 hours. GFP expression was observed at 36
hours with a maximal expression at 72 hours. Nystatin
(Sigma), methyl-β-cyclodextrin (Sigma) and chlorpro-Virology Journal 2007, 4:19 http://www.virologyj.com/content/4/1/19
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mazine (Alexis, San Diego Ca. 92121) were used at the
concentrations indicated. Nystatin, methyl-β-cyclodextrin
and chlorpromazine were added to Cos-7 or 293TT cells
30 minutes prior to infection. At 24 hours the media was
changed and fresh drug was added and maintained for an
additional 48 hours.
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